뼈의 재형성 및 무기질화

논문상세정보
    • 저자 신찬수 조화영
    • 제어번호 104732016
    • 학술지명 Endocrinology and metabolism
    • 권호사항 Vol. 20 No. 6 [ 2005 ]
    • 발행처 대한내분비학회
    • 발행처 URL http://www.endocrinology.or.kr
    • 자료유형 학술저널
    • 수록면 543-555
    • 언어 -
    • 출판년도 2005
    • 등재정보 KCI등재
    • 판매처
    유사주제 논문( 0)

' 뼈의 재형성 및 무기질화' 의 참고문헌

  • osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
    12 1260-1268 [1998]
  • a novel secreted protein involved in the regulation of bone density
    89 309-319 [1997]
  • Type I collagen: Structure, synthesis and regulation.
    1 - [2002]
  • The molecular clock mediates leptin-regulated bone formation
    122 803-815 [2005]
  • The biochemistry of bone
    1 107-188 [2001]
  • TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
    65 715-724 [1999]
  • Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin
    247 610-615 [1998]
  • Role of osteoblasts in hormonal control of bone resorption--a hypothesis
    349-351 [1981]
  • Rates of bone loss in the appendicular and axial skeletons of women Evidence of substantial vertebral bone loss before menopause
    1487-1491 [1986]
  • RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
    97 1566-1571 [2000]
  • RANK is essential for osteoclast and lymph node development
    13 2412-2424 [1999]
  • Quantitative computed tomography of vertebral spon- giosa a sensitive method for detecting early bone loss after oophorectomy
    699-705 [1982]
  • Parathyroid hormone stimulates bone formation and resorption in organ culture evidence for a coupling mechanism
    3204-3208 [1981]
  • Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release
    2398-2402 [1989]
  • Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development
    77 188--193 [1999]
  • Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    93 165-176 [1998]
  • Osteopontin and related phosphorylated sialoproteins
    760 249-256 [1995]
  • Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
    23 495-498 [1998]
  • OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    397 315-323 [1999]
  • Mineralization by matrix vesicles
    -964 [1984]
  • Mineral and collagen-binding proteins of fetal calf bone
    10403-10408 [1981]
  • Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone
    89 180--190 [2003]
  • Mechanism of calcification role of collagen fibrils and collagen-phosphoprotein complexes in vitro and in vivo
    139-153 [1989]
  • Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse
    endocri logy 127 2592-2594 [1990]
  • Leptin regulation of bone resorption by the sympathetic nervous system and CART
    434 514-520 [2005]
  • LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
    107 513-523 [2001]
  • Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs woven bone imply the existence of different underlying osteogenic mechanisms
    9 201-223 [1998]
  • Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass
    126 4267- 4279 [1999]
  • Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice
    5235-5239 [1988]
  • Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor- kappaB ligand and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene
    278 23971-23977 [2003]
  • In vivo stimulation of bone formation by transforming growth factor-beta
    endocri- logy 124 2991-2994 [1989]
  • Identifying genes that regulate bone remo- deling as potential therapeutic targets
    201 841-843 [2005]
  • Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat
    139 4012-4015 [1998]
  • Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures
    endocri logy 133 33-38 [1993]
  • Growth factors and the regulation of bone remodeling
    277-281 [1988]
  • Extracellular matrix and biomineralization of bone
    38-46 [2003]
  • Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shed- ding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.
    274 13613-13618 [1999]
  • Dynamics of bone remodeling
    315- [1964]
  • Characterization of the latent transforming growth factor beta complex in bone
    49-58 [1990]
  • Characterization of native and recombinant bone sialoprotein delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain
    12 1210-1222 [1997]
  • Basic principles and clinical applications of biochemical markers of bone metabolism
    2 299-321 [1999]
  • A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait
    70 11-19 [2002]